Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Microbiota-dependent signals are required to sustain TLR-mediated immune responses
Lehn K. Weaver, Danielle Minichino, Chhanda Biswas, Niansheng Chu, Jung-Jin Lee, Kyle Bittinger, Sabrin Albeituni, Kim E. Nichols, Edward M. Behrens
Lehn K. Weaver, Danielle Minichino, Chhanda Biswas, Niansheng Chu, Jung-Jin Lee, Kyle Bittinger, Sabrin Albeituni, Kim E. Nichols, Edward M. Behrens
View: Text | PDF
Research Article Inflammation

Microbiota-dependent signals are required to sustain TLR-mediated immune responses

  • Text
  • PDF
Abstract

Host-commensal interactions are critical for the generation of robust inflammatory responses, yet the mechanisms leading to this effect remain poorly understood. Using a murine model of cytokine storm, we identified that host microbiota are required to sustain systemic TLR-driven immune responses. Mice treated with broad-spectrum antibiotics or raised in germ-free conditions responded normally to an initial TLR signal but failed to sustain production of proinflammatory cytokines following administration of repeated TLR signals in vivo. Mechanistically, host microbiota primed JAK signaling in myeloid progenitors to promote TLR-enhanced myelopoiesis, which is required for the accumulation of TLR-responsive monocytes. In the absence of TLR-enhanced monocytopoiesis, antibiotic-treated mice lost their ability to respond to repeated TLR stimuli and were protected from cytokine storm–induced immunopathology. These data reveal priming of TLR-enhanced myelopoiesis as a microbiota-dependent mechanism that regulates systemic inflammatory responses and highlight a role for host commensals in the pathogenesis of cytokine storm syndromes.

Authors

Lehn K. Weaver, Danielle Minichino, Chhanda Biswas, Niansheng Chu, Jung-Jin Lee, Kyle Bittinger, Sabrin Albeituni, Kim E. Nichols, Edward M. Behrens

×

Figure 9

Pharmacologic inhibition of JAK1/2 signaling phenocopies the protection from TLR9-inudced immunopathology observed in antibiotic-treated mice.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacologic inhibition of JAK1/2 signaling phenocopies the protection ...
C57BL/6 mice were treated with 5 doses of PBS or CpG1826 over the course of 10 days. Mice received control chow or chow containing the JAK1/2 inhibitor ruxolitinib starting with the third injection. Numbers of bone marrow and spleen common myeloid progenitors (CMPs) (A) and inflammatory monocytes (iMonos) (B) were enumerated. (C) Clinical manifestations of cytokine storm were evaluated by measuring splenomegaly, hepatomegaly, anemia, and thrombocytopenia. Each graph displays representative data from one of 2 independent experiments (N = 5 mice per group). Analysis was performed by 2-way ANOVA (**P < 0.01, ****P < 0.0001, interaction; +P < 0.05, ++++P < 0.0001, control vs. ruxolitinib chow; #P < 0.05, ##P < 0.01, ####P < 0.0001, PBS vs. CpG in vivo treatments). The interaction term is CpG treatment x Ruxolitinib treatment.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts